Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a post hoc analysis of post-marketing surveillance data in Japan

Share

  • 1

    Paliperidone palmitate 3-month formulation (PP3M) shows high treatment continuation rates in Japanese schizophrenia patients, particularly without concomitant medications.

  • 2

    The 12-month treatment continuation rate for PP3M was reported at 84.7%, with higher rates for patients not using concomitant medications.

  • 3

    A starting dose of 175 mg of PP3M significantly increased the risk of treatment discontinuation, indicating the need for personalized dosing.

  • 4

    The treatment-related mortality rate was 3.94 per 1,000 person-years, with a standardized mortality ratio of 0.95 for the total population.

  • 5

    Stable concomitant medication use during PP3M treatment supports symptomatic stability and suggests the feasibility of monotherapy.

Original Source(s)

Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a post hoc analysis of post-marketing surveillance data in Japan

  • by Yoshiteru Takekita, Natsuko Tokushige, Yosuke Saga

  • March 18, 2026

Related Content

Can Biomarkers Refine Psych Dx?

Emerging evidence suggests biologic signals may predict treatment response and improve outcomes.

US Adolescent Sleep Loss Worsens Over 16 Years

Increase was driven largely by rising rates of very short sleep among high school students, with trends seen across demographic and behavioral groups.

Side Effects: Medicine's Blind Spot

Medicine is having a week: new insights on nutrition training, a rethink of “spring fatigue,” evidence that avocados may support artery health, and an AI that can spot rare hormone tumors from a hand photo